Edition:
United Kingdom

AbbVie Inc (ABBV.N)

ABBV.N on New York Stock Exchange

88.17USD
11 Dec 2018
Change (% chg)

$0.56 (+0.64%)
Prev Close
$87.61
Open
$88.62
Day's High
$89.44
Day's Low
$86.68
Volume
1,134,383
Avg. Vol
1,580,412
52-wk High
$125.84
52-wk Low
$77.50

Chart for

About

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology,... (more)

Overall

Beta: 1.53
Market Cap(Mil.): $144,249.59
Shares Outstanding(Mil.): 1,594.09
Dividend: 0.64
Yield (%): 2.83

Financials

  ABBV.N Industry Sector
P/E (TTM): 22.10 31.13 33.63
EPS (TTM): 4.09 -- --
ROI: 11.74 15.55 15.02
ROE: 113.57 16.92 16.60

AbbVie halts late-stage trial for lung cancer drug Rova-T

AbbVie Inc said on Wednesday it had halted enrollment for a late stage trial of Rova-T as a second-line therapy for advanced small-cell lung cancer, following recommendations made by an independent data monitoring committee.

05 Dec 2018

UPDATE 1-AbbVie halts late-stage trial for lung cancer drug Rova-T

Dec 5 AbbVie Inc said on Wednesday it had halted enrollment for a late stage trial of Rova-T as a second-line therapy for advanced small-cell lung cancer, following recommendations made by an independent data monitoring committee.

05 Dec 2018

AbbVie halts late-stage trial for lung cancer drug Rova-T

Dec 5 AbbVie said on Wednesday it had halted enrollment for a late stage trial of Rova-T as a second-line therapy for advanced small-cell lung cancer, following recommendations made by an independent data monitoring committee.

05 Dec 2018

JNJ-AbbVie cancer drug Imbruvica succeeds in late-stage trial

Johnson and Johnson said on Tuesday a combination therapy containing its blockbuster cancer drug Imbruvica significantly improved survival in blood cancer patients, compared with drugs currently used as the standard of care.

04 Dec 2018

UPDATE 1-JNJ-AbbVie cancer drug Imbruvica succeeds in late-stage trial

Dec 4 Johnson and Johnson said on Tuesday a combination therapy containing its blockbuster cancer drug Imbruvica significantly improved survival in blood cancer patients, compared with drugs currently used as the standard of care.

04 Dec 2018

JNJ-AbbVie cancer drug Imbruvica succeeds in late-stage trial

Dec 4 Johnson and Johnson said on Tuesday a combination therapy containing its blockbuster cancer drug Imbruvica significantly improved survival in blood cancer patients, compared with drugs currently used as the standard of care.

04 Dec 2018

FDA approves new blood cancer treatment from Pfizer

The U.S. Food and Drug Administration on Wednesday approved Pfizer Inc's drug to treat a form of blood cancer in newly diagnosed patients as a combination therapy.

21 Nov 2018

UPDATE 2-FDA approves new blood cancer treatment from Pfizer

Nov 21 The U.S. Food and Drug Administration on Wednesday approved Pfizer Inc's drug to treat a form of blood cancer in newly diagnosed patients as a combination therapy.

21 Nov 2018

Roche-AbbVie cancer drug gets accelerated FDA approval

Roche Holding AG said on Wednesday its cancer drug, Venclexta, received accelerated approval from the U.S. Food and Drug Administration as part of a combination treatment for newly diagnosed patients with a form of leukemia.

21 Nov 2018

CORRECTED-UPDATE 1-Roche-AbbVie cancer drug gets accelerated FDA approval

Nov 21 Roche Holding AG said on Wednesday its cancer drug, Venclexta, received accelerated approval from the U.S. Food and Drug Administration as part of a combination treatment for newly diagnosed patients with a form of leukemia.

21 Nov 2018

Earnings vs. Estimates